Type
1.
Deen J, Weber M, Jaenisch T. Dengue in the context of the integrated management of childhood illness. PLoS neglected tropical diseases [Internet]. 2016;10(8):e0004838. Available from: http://journals.plos.org/plosntds/article/asset?id=10.1371%2Fjournal.pntd.0004838.PDF
Type
1.
Cenderello G, Di Biagio A, Riccardi N, Taramasso L, De Maria A, Cassola G, et al. Increasing use and accessibility of anti parasitic drugs for migrants with neglected diseases at a time of migratory emergency. The new microbiologica [Internet]. 2016;39(3). Available from: http://www.newmicrobiologica.org/PUB/allegati_pdf/AOP/496M862.pdf
Type
1.
Feleke SM, Tadesse G, Mekete K Ethiopian Public Health Institute, Tekle AH, Kebede A. Epidemiological mapping of human onchocerciasis in transmission suspected districts of Bale, Borena, and West Arsi zones of Eastern Ethiopia. Interdisciplinary Perspectives on Infectious Diseases. 2016;2016.
Type
1.
Bockarie M, Rebollo M. Reducing the population requiring interventions against lymphatic filariasis in Africa. The Lancet. Global health [Internet]. 2016;4(3):e154-5. Available from: http://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(15)00292-2.pdf
Type
1.
Bradbury R, Graves P. Current WHO protocols for mass drug administration in helminth control. Microbiology Australia [Internet]. 2016;37:10–12. Available from: http://microbiology.publish.csiro.au/?act=view_file&file_id=MA16004.pdf
Type
1.
Mphande FA. Poverty, health and livelihoods. In: Infectious Diseases and Rural Livelihood in Developing Countries. Springer; 2016. pp. 1–16.
Type
1.
Babu B, Babu G. Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2014;108(9):538-49.
Type
1.
Boyd A, Won K, McClintock S, Donovan C, Laney S, Williams S, et al. A community-based study of factors associated with continuing transmission of lymphatic filariasis in Leogane, Haiti. PLoS neglected tropical diseases [Internet]. 2010;4(3):e640. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843627/pdf/pntd.0000640.pdf
Type
1.
Ezeigbo O, Nwoke B, Ukaga C, Emecheta R. Willingness of individuals to comply with annual and long-term ivermectin treatment in Abia State, Nigeria. British Journal of Medicine and Medical Research. 2014;4:2212-9.
Type
1.
Rahman S. Pharmaceutical progress for neglected diseases: using non-traditional development. [Internet]. Duke University; 2015. Available from: http://dukespace.lib.duke.edu/dspace/bitstream/handle/10161/11403/Rahman_duke_0066N_13200.pdf?sequence=1